ATE339689T1 - Verfahren zur identifizierung von rage- modulierenden verbindungen - Google Patents

Verfahren zur identifizierung von rage- modulierenden verbindungen

Info

Publication number
ATE339689T1
ATE339689T1 AT01941698T AT01941698T ATE339689T1 AT E339689 T1 ATE339689 T1 AT E339689T1 AT 01941698 T AT01941698 T AT 01941698T AT 01941698 T AT01941698 T AT 01941698T AT E339689 T1 ATE339689 T1 AT E339689T1
Authority
AT
Austria
Prior art keywords
rage
antibody
fragment
ligand
binds
Prior art date
Application number
AT01941698T
Other languages
English (en)
Inventor
Manouchehr Shahbaz
Original Assignee
Trans Tech Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Trans Tech Pharma Inc filed Critical Trans Tech Pharma Inc
Application granted granted Critical
Publication of ATE339689T1 publication Critical patent/ATE339689T1/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Biochemistry (AREA)
  • Food Science & Technology (AREA)
  • Neurosurgery (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Neurology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Reproductive Health (AREA)
  • Rheumatology (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Gynecology & Obstetrics (AREA)
AT01941698T 2000-05-30 2001-05-30 Verfahren zur identifizierung von rage- modulierenden verbindungen ATE339689T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US20734200P 2000-05-30 2000-05-30
US09/799,152 US6908741B1 (en) 2000-05-30 2001-03-05 Methods to identify compounds that modulate RAGE

Publications (1)

Publication Number Publication Date
ATE339689T1 true ATE339689T1 (de) 2006-10-15

Family

ID=26902166

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01941698T ATE339689T1 (de) 2000-05-30 2001-05-30 Verfahren zur identifizierung von rage- modulierenden verbindungen

Country Status (11)

Country Link
US (3) US6908741B1 (de)
EP (1) EP1305635B1 (de)
JP (1) JP4723792B2 (de)
AT (1) ATE339689T1 (de)
AU (1) AU782461B2 (de)
CA (1) CA2379521C (de)
DE (1) DE60123075T2 (de)
DK (1) DK1305635T3 (de)
ES (1) ES2271028T3 (de)
MX (1) MXPA02001103A (de)
WO (1) WO2001092892A2 (de)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7258857B2 (en) * 1996-11-22 2007-08-21 The Trustees Of Columbia University In The City Of New York Rage-related methods for treating inflammation
US6908741B1 (en) * 2000-05-30 2005-06-21 Transtech Pharma, Inc. Methods to identify compounds that modulate RAGE
JP3837494B2 (ja) * 2001-03-19 2006-10-25 国立大学法人金沢大学 可溶型ｒａｇｅタンパク質
WO2005051995A2 (en) * 2003-11-19 2005-06-09 Curagen Corporation Novel advanced glycosylation end product-specific receptor-like protein and nucleic acids encoding same
AU2005223660B2 (en) * 2004-03-18 2011-06-23 Transtech Pharma, Inc. Fluorescence polarization assay
JP2005337952A (ja) * 2004-05-28 2005-12-08 Kanazawa Univ Tlo Inc 生活習慣病予知因子
CN1993378A (zh) * 2004-08-03 2007-07-04 转化技术制药公司 Rage融合蛋白及使用方法
EP1799700A4 (de) * 2004-09-27 2009-02-11 Centocor Inc Srage-mimetikörper, -zusammensetzungen, -verfahren und -verwendungen
DE102005002353A1 (de) * 2005-01-18 2006-07-27 Abbott Gmbh & Co. Kg AGER-Rezeptor Multimerisierungs Epitope
US9291621B2 (en) 2005-01-18 2016-03-22 AbbVie Deutschland GmbH & Co. KG AGER-peptides and use thereof
EP1838339A2 (de) * 2005-01-18 2007-10-03 Abbott GmbH & Co. KG Ager-peptide und deren verwendung
WO2006119510A2 (en) * 2005-05-04 2006-11-09 Receptor Biologix, Inc. Isoforms of receptor for advanced glycation end products (rage) and methods of identifying and using same
ES2580108T3 (es) * 2005-07-11 2016-08-19 Aerie Pharmaceuticals, Inc Compuestos de isoquinolina
US20070135499A1 (en) * 2005-07-11 2007-06-14 Aerie Pharmaceuticals, Inc. Hydrazide compounds
WO2007044309A2 (en) * 2005-10-05 2007-04-19 Vasix Corporation Device and method for inhibiting age complex formation
CN101410411A (zh) * 2006-02-09 2009-04-15 转化技术制药公司 Rage融合蛋白及使用方法
ES2729424T3 (es) 2006-09-20 2019-11-04 Aerie Pharmaceuticals Inc Inhibidores de Rho cinasa
US8455513B2 (en) 2007-01-10 2013-06-04 Aerie Pharmaceuticals, Inc. 6-aminoisoquinoline compounds
US20080199467A1 (en) * 2007-02-15 2008-08-21 Mjalli Adnan M M Immunoglobulin fusion proteins and methods of making
EP2158210B1 (de) 2007-06-14 2015-12-09 Galactica Pharmaceuticals, Inc. Rage-fusionsproteine
JP2009082076A (ja) * 2007-09-28 2009-04-23 National Agriculture & Food Research Organization 変異受容体、ならびにこれを用いる生活習慣病関連因子検出方法
US20110311448A1 (en) * 2007-11-02 2011-12-22 Ann Marie Schmidt Antibody to rage and uses for in vivo imaging or for targeting therapy
US8455514B2 (en) * 2008-01-17 2013-06-04 Aerie Pharmaceuticals, Inc. 6-and 7-amino isoquinoline compounds and methods for making and using the same
RU2518351C2 (ru) 2008-05-09 2014-06-10 Эббви Дойчланд Гмбх Унд Ко.Кг, Антитела к рецептору конечных продуктов глубокого гликирования (rage) и их применения
US8450344B2 (en) * 2008-07-25 2013-05-28 Aerie Pharmaceuticals, Inc. Beta- and gamma-amino-isoquinoline amide compounds and substituted benzamide compounds
CN102803292A (zh) 2009-04-20 2012-11-28 辉瑞公司 蛋白质糖基化的控制及其相关组合物和方法
EP3828172A1 (de) 2009-05-01 2021-06-02 Aerie Pharmaceuticals, Inc. Hemmer mit doppelmechanismus zur behandlung von erkrankungen
WO2011102845A1 (en) 2010-02-18 2011-08-25 Transtech Pharma, Inc. Rage fusion protein compositions and methods of use
KR101595630B1 (ko) * 2013-01-18 2016-02-18 성균관대학교산학협력단 Rage 단백질-베타아밀로이드 상호작용 억제제, 및 이를 유효성분으로 함유하는 베타아밀로이드 집적 관련 질환의 예방 또는 치료용 약학적 조성물
US20140275160A1 (en) 2013-03-15 2014-09-18 Aerie Pharmaceuticals, Inc. Combination therapy
CN103376328A (zh) * 2013-07-18 2013-10-30 上海交通大学医学院附属瑞金医院 血清sRAGE水平的检测试剂在筛选改善胰岛素β细胞功能的糖尿病治疗药物中的应用
JP6445861B2 (ja) * 2014-12-18 2018-12-26 国立大学法人金沢大学 オキシトシン検出のためのサンプルの前処理方法
WO2016171573A1 (es) * 2015-01-14 2016-10-27 Instituto De Investigaciones Científicas Y Servicios De Alta Tecnología Aip (Indicasat Aip) Procedimiento para la detección de moléculas que inhiban la interacción de la proteína cd36 con el beta amiloide
US9643927B1 (en) 2015-11-17 2017-05-09 Aerie Pharmaceuticals, Inc. Process for the preparation of kinase inhibitors and intermediates thereof
JP6832946B2 (ja) 2015-11-17 2021-02-24 アエリエ ファーマシューティカルズ インコーポレイテッド キナーゼ阻害剤およびその中間体の調製方法
CN109640966A (zh) 2016-08-31 2019-04-16 爱瑞制药公司 眼用组合物
WO2018183911A1 (en) 2017-03-31 2018-10-04 Aerie Pharmaceuticals, Inc. Aryl cyclopropyl-amino-isoquinolinyl amide compounds
US11427563B2 (en) 2018-09-14 2022-08-30 Aerie Pharmaceuticals, Inc. Aryl cyclopropyl-amino-isoquinolinyl amide compounds

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4166452A (en) 1976-05-03 1979-09-04 Generales Constantine D J Jr Apparatus for testing human responses to stimuli
US4356108A (en) 1979-12-20 1982-10-26 The Mead Corporation Encapsulation process
US4265874A (en) 1980-04-25 1981-05-05 Alza Corporation Method of delivering drug with aid of effervescent activity generated in environment of use
US5202424A (en) 1984-03-19 1993-04-13 The Rockefeller University Mesangial cell-derived receptors for advanced glycosylation endproducts and uses thereof
US5585344A (en) 1984-03-19 1996-12-17 The Rockefeller University Liver-derived receptors for advanced glycosylation endproducts and uses thereof
US4873313A (en) 1985-01-18 1989-10-10 Beckman Research Institute Of City Of Hope Specific hybridoma cell line and monocolonal antibodies produced from such specific hybridoma cell line and method of using such monoclonal antibodies to detect carcinoembryonic antigens
US5939536A (en) 1990-03-05 1999-08-17 Genzyme Corporation Methods for purifying cystic fibrosis transmembrane conductance regulation
AU1832797A (en) 1996-01-26 1997-08-20 Trustees Of Columbia University In The City Of New York, The A polypeptide from lung extract which binds amyloid-beta peptide
US5864018A (en) 1996-04-16 1999-01-26 Schering Aktiengesellschaft Antibodies to advanced glycosylation end-product receptor polypeptides and uses therefor
AU2696097A (en) 1996-04-16 1997-11-07 Schering Aktiengesellschaft Advanced glycosylation end-product receptor peptides and uses therefor
US5876944A (en) * 1996-06-10 1999-03-02 Bayer Corporation Method for amplification of the response signal in a sandwich immunoassay
US5688653A (en) 1996-06-27 1997-11-18 The Picower Institute For Medical Research 3-alkylamino-2-hydroxy-4-hydroxymethyl-2-cyclopenten-1-one advanced glycosylation endproducts and methods of use therefor
US6555651B2 (en) * 1997-10-09 2003-04-29 The Trustees Of Columbia University In The City Of New York Ligand binding site of rage and uses thereof
US6790443B2 (en) 1996-11-22 2004-09-14 The Trustees Of Columbia University In The City Of New York Method for treating symptoms of diabetes
US7081241B1 (en) * 1998-10-06 2006-07-25 The Trustees Of Columbia University In The City Of New York Extracellular rage binding protein (EN-RAGE) and uses thereof
US6100098A (en) 1997-02-18 2000-08-08 Mcgill University Anti-AGE IgG and uses thereof for the diagnosis of severe disease
US7101838B2 (en) 1997-08-05 2006-09-05 The Trustees Of Columbia University In The City Of New York Method to prevent accelerated atherosclerosis using (sRAGE) soluble receptor for advanced glycation endproducts
US6465422B1 (en) 1998-04-17 2002-10-15 The Trustees Of Columbia University In The City Of New York Method for inhibiting tumor invasion or spreading in a subject
US6753150B2 (en) 1998-10-05 2004-06-22 The Trustees Of Columbia University In The City Of New York Method for determining whether a compound is capable of inhibiting the interaction of a peptide with rage
ES2299267T3 (es) 1998-10-06 2008-05-16 The Trustees Of Columbia University In The City Of New York Nueva proteina extracelular ligante de rage (en-rage) y sus usos.
US6908741B1 (en) * 2000-05-30 2005-06-21 Transtech Pharma, Inc. Methods to identify compounds that modulate RAGE

Also Published As

Publication number Publication date
EP1305635B1 (de) 2006-09-13
DK1305635T3 (da) 2007-01-22
AU782461B2 (en) 2005-07-28
WO2001092892A2 (en) 2001-12-06
US6908741B1 (en) 2005-06-21
AU7502901A (en) 2001-12-11
JP4723792B2 (ja) 2011-07-13
US7374891B2 (en) 2008-05-20
WO2001092892A3 (en) 2003-02-27
US20080293163A1 (en) 2008-11-27
DE60123075D1 (de) 2006-10-26
US20060078956A1 (en) 2006-04-13
CA2379521A1 (en) 2001-12-06
CA2379521C (en) 2006-04-04
JP2003535339A (ja) 2003-11-25
EP1305635A2 (de) 2003-05-02
DE60123075T2 (de) 2007-03-01
MXPA02001103A (es) 2003-07-21
ES2271028T3 (es) 2007-04-16

Similar Documents

Publication Publication Date Title
DE60123075D1 (de) Verfahren zur identifizierung von rage-modulierenden verbindungen
DE602004024236D1 (en) Assay
EA202092087A1 (ru) Анализы для выявления нейродегенеративных заболеваний
DE60033555D1 (de) Verfahren und zusammestellungen zum nachweis und behandlung von brustkrebs, beruhend auf brustkrebs-assoziierten polypeptiden
MX337569B (es) Ligandos de proteina prion y metodos de uso.
ATE517123T1 (de) Anti-gpr-9-6 und anti-teck gerichtete antikörper und verfahren zur identifizierung von modulatoren der gpr-9-6 und teck funktion
ATE473754T1 (de) Verfahren zur manipulation der zelldifferenzierung
ATE332505T1 (de) Verfahren und zusammensetzung zur auffindung von cervix-krebs
CY1107490T1 (el) Μεθοδος για την ταυτοποιηση δειγματος σε θηλαστικα καθως και κιτ για την εκτελεση αυτης της μεθοδου
ATE476525T1 (de) Verfahren zum nachweis von mit endometrialer krankheit oder phase assoziierten markern
ATE452338T1 (de) Nachweisverfahren für eine frühe nierenkrankheit in tieren
MY157955A (en) Detection of a target antigen irrespective of the presence or absence of a corresponding therapeutic antibody
EP2074427A4 (de) Diagnostik-biomolekül(e)
WO2006034278A3 (en) Methods and compositions for detecting cancer using components of the u2 spliceosomal particle
MX2025009067A (es) Metodos para cuantificar la il-33
WO2004077057A8 (en) Standard for immunohistochemistry, immunocytochemistry and molecular cytogenetics
WO2005019831B1 (en) Methods for reducing complexity of a sample using small epitope antibodies
WO2001021826A3 (de) Nachweis des pyruvatkinase-isoenzyms im stuhl
DE59606129D1 (de) Verfahren und verbindungen zur detektion von analyten mittels remanenzmessung und deren verwendung
Mitsuhashi et al. Improved method for the determination of kynurenic acid in rat plasma by column-switching HPLC with post-column fluorescence detection
EP1724589A3 (de) Verfahren zur identifizierung von rage-modulierenden verbindungen
EP1476757A4 (de) Verfahren und kit zur krebsvorhersage
CY1107474T1 (el) Χρηση 13c-nmr για να ανιχνευεται συνδεση
FI3986588T3 (fi) HPCL pohjainen flokkulaatio aineiden tunnistus proteiini näytteestä
WO2004039963A3 (en) Antibodies specific for phosphorylated insulin receptor substrate-1/2 (ser 1101/ser1149) and uses thereof

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1305635

Country of ref document: EP